Telmisartan, ramipril, or both in patients at high risk for vascular events
Ontarget Investigators - New England Journal of Medicine, 2008 - Mass Medical Soc
Background In patients who have vascular disease or high-risk diabetes without heart
failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from …
failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from …
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the …
Ontarget/transcend Investigators - American heart journal, 2004 - Elsevier
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce mortality,
myocardial infarction, stroke, heart failure, need for revascularization, nephropathy, and …
myocardial infarction, stroke, heart failure, need for revascularization, nephropathy, and …
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a …
Telmisartan Randomised AssessmeNt Study in ACE … - The Lancet, 2008 - Elsevier
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce major
cardiovascular events, but are not tolerated by about 20% of patients. We therefore …
cardiovascular events, but are not tolerated by about 20% of patients. We therefore …
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
JFE Mann, RE Schmieder, M McQueen, L Dyal… - The Lancet, 2008 - thelancet.com
Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE)
inhibitors are known to reduce proteinuria. Their combination might be more effective than …
inhibitors are known to reduce proteinuria. Their combination might be more effective than …
Safety of telmisartan in patients with arterial hypertension: an open-label observational study
MC Michel, H Bohner, J Köster, R Schäfers… - Drug Safety, 2004 - Springer
Objective: To determine whether age, gender, concomitant disease and/or previous or
present antihypertensive medication affect the safety or antihypertensive efficacy of …
present antihypertensive medication affect the safety or antihypertensive efficacy of …
Angiotensin II and trials of cardiovascular outcomes
P Sleight - The American journal of cardiology, 2002 - Elsevier
Proven cardiovascular benefit from angiotensin-converting enzyme (ACE) inhibition is a
cornerstone of evidence-based medicine. The first study to show dramatic benefits from ACE …
cornerstone of evidence-based medicine. The first study to show dramatic benefits from ACE …
Effect of telmisartan on renal outcomes: a randomized trial
JFE Mann, RE Schmieder, L Dyal… - Annals of internal …, 2009 - acpjournals.org
Background: Angiotensin-receptor blockers (ARBs) blunt progression of advanced diabetic
nephropathy, but their long-term renal effects in other patients are not clear. Objective: To …
nephropathy, but their long-term renal effects in other patients are not clear. Objective: To …
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in …
J Cheng, W Zhang, X Zhang, F Han, X Li… - JAMA internal …, 2014 - jamanetwork.com
Importance Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with …
blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with …
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
P Sleight, J Redon, P Verdecchia, G Mancia… - Journal of …, 2009 - journals.lww.com
Background Hypertension guidelines advise aggressive blood pressure (BP) lowering in
patients with diabetes or high cardiovascular risk, but supporting evidence is limited. We …
patients with diabetes or high cardiovascular risk, but supporting evidence is limited. We …
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis
S Yusuf - The American journal of cardiology, 2002 - Elsevier
The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that
ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of …
ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of …